In vivo CAR-T cell therapy: New breakthroughs for cell-based tumor immunotherapy.

Area of Science:

• Oncology
• Immunotherapy
• Gene Therapy

Background:

• Chimeric antigen receptor (CAR)-T cell immunotherapy is a significant advancement in cancer treatment.
• Current CAR-T cell therapies face challenges including complex manufacturing, high costs, and lengthy processes.

Purpose of the Study:

• To review key platforms for in vivo gene delivery.
• To discuss the progress of in vivo CAR-T cell therapy for cancer treatment.
• To highlight advancements in safety, effectiveness, and clinical applications.

Main Methods:

• Review of in vivo gene delivery systems.
• Analysis of advancements in gene editing technologies and CAR structures.
• Examination of clinical progress in in vivo CAR-T cell therapy.

Main Results:

• In vivo CAR-T cell therapy is emerging as a promising approach to improve anti-tumor effectiveness and safety.
• Optimized gene delivery, gene editing, and CAR structures have enhanced in vivo CAR-T therapies.
• Significant progress has been made in the clinical application of these therapies.

Conclusions:

• In vivo CAR-T cell therapy presents a viable strategy to overcome limitations of traditional CAR-T cell treatments.
• Further research is needed to address challenges such as gene delivery safety, CAR-T cell persistence, and the immunosuppressive tumor microenvironment.